AIRLINK 80.30 Increased By ▲ 1.91 (2.44%)
BOP 5.27 Decreased By ▼ -0.07 (-1.31%)
CNERGY 4.37 Increased By ▲ 0.04 (0.92%)
DFML 31.53 Increased By ▲ 0.66 (2.14%)
DGKC 77.00 Decreased By ▼ -1.51 (-1.92%)
FCCL 20.27 Decreased By ▼ -0.31 (-1.51%)
FFBL 31.35 Decreased By ▼ -0.95 (-2.94%)
FFL 9.84 Decreased By ▼ -0.38 (-3.72%)
GGL 10.30 Increased By ▲ 0.01 (0.1%)
HBL 117.50 Decreased By ▼ -1.00 (-0.84%)
HUBC 134.38 Decreased By ▼ -0.72 (-0.53%)
HUMNL 6.87 No Change ▼ 0.00 (0%)
KEL 4.50 Increased By ▲ 0.33 (7.91%)
KOSM 4.73 No Change ▼ 0.00 (0%)
MLCF 37.65 Decreased By ▼ -1.02 (-2.64%)
OGDC 133.40 Decreased By ▼ -1.45 (-1.08%)
PAEL 23.31 Decreased By ▼ -0.09 (-0.38%)
PIAA 26.52 Decreased By ▼ -0.12 (-0.45%)
PIBTL 7.00 Decreased By ▼ -0.02 (-0.28%)
PPL 112.71 Decreased By ▼ -0.74 (-0.65%)
PRL 27.59 Decreased By ▼ -0.14 (-0.5%)
PTC 14.68 Increased By ▲ 0.08 (0.55%)
SEARL 57.55 Increased By ▲ 1.05 (1.86%)
SNGP 66.75 Increased By ▲ 0.45 (0.68%)
SSGC 10.91 Decreased By ▼ -0.03 (-0.27%)
TELE 9.25 Increased By ▲ 0.10 (1.09%)
TPLP 11.62 Decreased By ▼ -0.05 (-0.43%)
TRG 72.36 Increased By ▲ 0.93 (1.3%)
UNITY 24.82 Increased By ▲ 0.31 (1.26%)
WTL 1.39 Increased By ▲ 0.06 (4.51%)
BR100 7,466 Decreased By -26.9 (-0.36%)
BR30 24,514 Decreased By -44.3 (-0.18%)
KSE100 71,714 Decreased By -337.5 (-0.47%)
KSE30 23,635 Decreased By -172.4 (-0.72%)
World

Philippines to evaluate China's Sinopharm COVID-19 vaccine for emergency use

  • Sinopharm is the sixth vaccine maker to apply for emergency use authorisation in the Southeast Asian country.
Published March 2, 2021

MANILA: China's Sinopharm has applied for emergency use of its COVID-19 vaccine in the Philippines, the chief of Manila's Food and Drug Administration (FDA) said on Tuesday.

Sinopharm is the sixth vaccine maker to apply for emergency use authorisation in the Southeast Asian country.

The Philippines, which has the second-highest number of COVID-19 cases and deaths in Southeast Asia, has approved the vaccines of Pfizer, AstraZeneca and Sinovac for emergency use.

Comments

Comments are closed.